Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high‐risk patients – a POCER study analysis

@article{DeCruz2015EfficacyOT,
  title={Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high‐risk patients – a POCER study analysis},
  author={Peter De Cruz and M A Kamm and Amy L. Hamilton and K J Ritchie and Efrosinia O. Krejany and Alexandra Gorelik and Danny Liew and Lani Prideaux and Ian C. Lawrance and Jane M. Andrews and Peter A. Bampton and Simon L Jakobovits and Timothy H. Florin and Peter R. Gibson and Henry S Debinski and Richard B. Gearry and Finlay Macrae and Rupert W L Leong and Ian J Kronborg and Graham L. Radford-Smith and Warwick S. Selby and Michael J. Johnston and Russell Woods and Peter R. Elliott and Sally J. Bell and S J Brown and William R. Connell and Paul Vincent Desmond},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2015},
  volume={42}
}
Crohn's disease recurs in the majority of patients after intestinal resection. 
View on Wiley
onlinelibrary.wiley.com
86 Citations
Highly Influential Citations
1
Background Citations
7
Methods Citations
4
Results Citations
2

86 Citations

Citation Type

Citation Type

Male gender, active smoking and previous intestinal resection are risk factors for post‐operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study
After ileocaecal resection for Crohn's disease (CD), inflammatory lesions frequently recur on the anastomosis and/or on the neo‐terminal ileum.
Letter: management of post‐operative Crohn's disease ‐ thiopurines vs adalimumab– authors' reply
TLDR
The POCER study confirmed, for the first time prospectively, that smoking, previous surgery, and penetrating disease are predictors of recurrence, even in the setting of risk-stratified drug therapy.
Postoperative Crohn’s Disease
TLDR
This chapter will cover prognostic and predictive biomarkers that have been identified in association with postoperative recurrence of Crohn’s disease to help guide clinical management and identify future directions for ongoing research.
Visceral adiposity predicts post‐operative Crohn's disease recurrence
TLDR
Excessive visceral adipose tissue has been associated with poorer outcomes in patients with inflammatory bowel disease and should be considered a major concern.
Does anti‐tumor necrosis factor alpha prevent the recurrence of Crohn's disease? Systematic review and meta‐analysis
TLDR
A systematic review and meta‐analysis was conducted to evaluate both the efficacy of anti‐TNF therapy after stratification by the outcome of interest and the AEs.
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting
TLDR
Anti-TNF therapy was the most effective strategy for the prevention of endoscopic Crohn's disease recurrence and was more effective than thiopurines or mesalazine.
Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era
  • G. Mantzaris
  • Medicine
    Current Treatment Options in Gastroenterology
  • 2017
TLDR
Thiopurine-naïve ulcerative colitis patients with iv corticosteroid-refractory disease, thiopurines offer an excellent maintenance strategy after cyclosporine rescue therapy and prevent the postoperative recurrence of Crohn’s disease, especially in smokers, and can achieve response or remission in uncomplicated perianal fistulizing disease.
Cessation of Biologics: Can It Be Done?
TLDR
This book chapter will focus on the why, when, who might consider cessation of anti-TNF-α therapy, and how this may be best performed.
Anti-TNFα agents are the best choice in preventing postoperative Crohn's disease: A meta-analysis.
  • A. Erős, N. Farkas, +12 authors P. Sarlós
  • Medicine
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2019
Medical therapies for postoperative Crohn’s disease
TLDR
Evidence behind postoperative recurrence rates, disease monitoring techniques, nonbiologic and biologic therapies available to prevent and treat postoperative Recurrence, risk factors associated with recurrence, and postoperative management strategies guided by endoscopic monitoring are summarized.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 63 REFERENCES
Review article: the natural history of postoperative Crohn's disease recurrence
Surgical resection of the diseased bowel in Crohn's disease is unfortunately not curative, and postoperative recurrence remains a problem in these patients.
Meta‐analysis: targeting the intestinal microbiota in prophylaxis for post‐operative Crohn’s disease
Aliment Pharmacol Ther 31, 802–809
546 Validation of a Magnetic Resonance Index of Activity for Ileocolonic Crohn's Disease
Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial
TLDR
The administration of adalimumab after intestinal resective surgery was greatly effective in preventing endoscopic and clinical recurrence of CD.
Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis
TLDR
The role of 5-ASAs in inducing remission of active CD and preventing relapse of quiescent CD remains uncertain, and more RCTs are required.
Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn’s disease
Aliment Pharmacol Ther 2011; 34: 125–145
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
TLDR
Mortality was similar between infliximab- and other-treatments-only-treated CD patients, although CD severity and use of prednisone or narcotic analgesics carried higher risks, and an increased risk of serious infection with inflIXimab was observed.
Postoperative recurrent luminal Crohn's disease: a systematic review.
TLDR
A number of clinical risk factors for the development of earlier postoperative recurrence have been identified, and reasonable evidence is now available regarding the efficacy of drug therapies in preventing recurrence.
Surgery for adult Crohn's disease: what is the actual risk?
TLDR
The aim of this article is to review the risk of surgery before and in the era of biologics and to discuss the impact of medications on this risk, with a focus on adult luminal CD.
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study.
...
1
2
3
4
5
...